New Study Demonstrates Ropeginterferon Alfa-2b-njft Is a Cos

BURLINGTON, Mass., August 04, 2023--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced the publication of a cost-effectiveness analysis of ropeginterferon alfa-2b-njft (marketed as BESREMi®) in the Journal of Comparative Effectiveness Research. The analysis, titled "Cost-Effectiven

Related Keywords

United States , Japan , South Korea , Taiwan , China , Taipei , T Ai Pei , Taiwanese , American , Raymond Urbanski , Pharmaessentia Tpex , Aaron Gerds , Ann Hematol , Pharmaessentia United States Corporation , Institute For Clinical , Pharmaessentia Corporation , Journal Of Comparative Effectiveness Research , Pharmaessentia Corporation Tpex , Linkedin , Affairs At Pharmaessentia , Us Head Of Clinical Development , Case Comprehensive Cancer Center , National Comprehensive Cancer Network , Bonafedem Health Care , European Medicines Agency , Comparative Effectiveness Research , Comparative Effectiveness , Polycythemia Vera , Medical Director , Senior Vice President , Clinical Development , Medical Affairs , Pharmaessentia United States , Peripheral Blood Counts , Reproductive Potential , Prescribing Information , Private Securities Litigation Reform Act , What We Know , What We Do Not Know , Emerging Treatment , Clin Oncol , Care Costs , Thromboembolic Events , Hydroxyurea Treated Patients , Economic Review , Fibrotic Progression , Essential Thrombocythemia , Literature Review , Cost Effectiveness Analysis , Tv , Healthcare System , Effective Therapy , Interferon Alfa 2b ,